develop
highli
effect
broadspectrum
antivir
agent
major
object
share
field
virolog
pharmaceut
antivir
drug
develop
focus
target
viral
entri
replic
well
modul
cellular
defens
system
high
throughput
screen
molecul
genet
engin
peptid
function
screen
agent
identifi
promis
candid
develop
optim
broadspectrum
antivir
agent
interven
viral
infect
control
viral
epidem
review
discuss
current
knowledg
prospect
applic
opportun
challeng
develop
broadspectrum
antivir
agent
epidem
viral
diseas
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
westerneastern
equin
enceph
weeeee
ebola
well
pandem
influenza
occur
respect
emerg
sar
mer
well
reemerg
weeeee
ebov
lethal
transmiss
travel
identifi
high
prioriti
biodefens
pathogen
unit
state
high
virul
virus
absenc
effect
therapi
pose
ongo
threat
public
health
convent
onebugonedrug
paradigm
insuffici
address
challeng
emerg
reemerg
viral
pathogen
drug
current
avail
prompt
control
epidem
viral
diseas
chan
et
al
raveh
et
al
carossino
et
al
thu
imper
develop
broadspectrum
class
antivir
agent
current
strategi
develop
broadspectrum
antivir
agent
focu
two
aspect
target
viral
infect
modul
host
defens
system
discuss
review
current
strategi
control
viral
infect
focu
identif
agent
capabl
interven
essenti
step
viral
infect
includ
viral
attach
fusionendocytosi
replic
assembl
bud
addit
drug
target
viral
envelop
detail
follow
subsect
tabl
figur
viral
attach
host
cell
specif
interact
viral
surfac
protein
host
cell
surfac
receptor
critic
step
viral
entri
cell
thu
block
interact
viral
particl
host
cell
import
task
serious
consid
develop
broadspectrum
antivir
agent
control
viral
infect
ifv
ifva
infect
host
cell
interact
surfac
antigen
haemagglutinin
host
cell
surfac
receptor
complex
contain
sialic
acid
nichol
et
al
highli
conserv
epitop
membraneproxim
stem
hemagglutinin
success
target
specif
monoclon
antibodi
inhibit
ifva
infect
via
block
conform
chang
haemagglutinin
viral
attach
host
cell
preor
posttreat
mice
effect
inhibit
infect
variou
serotyp
ifv
protect
anim
ifv
infect
demonstr
potenti
broadspectrum
antivir
agent
friesen
et
al
hand
sialic
acid
host
cell
surfac
receptor
also
recogn
target
develop
broadspectrum
antivir
agent
sialidas
hydrolyz
cell
surfac
sialic
acid
prevent
viral
attach
cell
sialidas
fusion
protein
consist
sialidas
enzymat
domain
amphiregulin
glycosaminoglycan
bind
sequenc
respiratori
epithelium
shown
effici
protect
mice
infect
variou
serotyp
ifv
well
piv
treatment
ifvinfect
anim
also
prevent
pneumonia
indic
treatment
prevent
anim
secondari
bacteri
infect
hedlund
et
al
thu
candid
develop
broadspectrum
antivir
agent
control
infect
ifv
variant
particl
carri
one
envelop
glycoprotein
precursor
cleav
host
proteas
furin
result
bind
cell
surfac
receptor
coreceptor
viral
attach
entri
cell
wilen
et
al
three
reagent
silver
ovalbumin
ova
lectin
consid
develop
broadspectrum
antivir
agent
costeffici
materi
antivir
agent
develop
silver
common
expedi
cook
procedur
preserv
water
contamin
coat
nanosilv
polyvinylpyrrolidon
pvp
shown
competit
bind
result
block
viral
attach
host
cell
receptor
prevent
viral
infect
galdiero
et
al
addit
pvpcoat
nanosilv
exhibit
antivir
abil
directli
inhibit
infect
viral
particl
cellindepend
manner
lara
et
al
howev
metal
nanoparticl
may
interfer
infect
viral
particl
develop
broadspectrum
antivir
agent
remain
investig
similarli
ova
show
antivir
abil
phthalic
anhydridemodifi
ova
hpova
exhibit
broadspectrum
antivir
activ
interf
bind
li
et
al
mani
natur
lectin
concanavalin
lentil
lectin
isol
plant
shown
cytotox
nonspecif
activ
cell
agglutin
red
blood
cell
concern
limit
use
lectin
antivir
drug
develop
barton
et
al
mori
group
reveal
kda
red
alga
lectin
griffithsin
grft
bind
nglycan
termin
mannos
residu
block
viral
bind
cell
inhibit
entri
cell
glycosylationdepend
manner
mori
et
al
grft
shown
possess
broadspectrum
antivir
activ
potenti
safe
system
treatment
infect
without
induc
proinflammatori
cytokin
mori
et
al
barton
et
al
cyanovirinn
cvn
natur
lectin
isol
cyanobacterium
nostoc
ellipsosporum
shown
highaffin
interact
nlink
highmannos
oligosaccharid
hiv
block
abil
mediat
membran
fusion
boto
wlodaw
howev
associ
cytotox
immunogen
hinder
develop
cvn
viabl
therapeut
agent
cvn
also
inhibit
eobv
hcv
infect
effect
interact
viral
envelop
glycoprotein
earli
stage
viral
entri
barriento
et
al
hell
et
al
recent
gggg
flexibl
hydrophil
linker
use
conjug
cvn
produc
lcvn
peg
use
modifi
nterminu
lcvn
produc
pegyl
lcvn
peglcvn
peglcvn
effect
control
ifn
infect
vivo
wu
et
al
accordingli
cvn
deriv
peglcvn
develop
use
broadspectrum
antivir
agent
thu
pvpcoat
nanosilv
particl
hpova
grft
cvn
studi
develop
broadspectrum
antivir
agent
control
infect
broadspectrum
neutral
antibodi
bnab
develop
target
hiv
inhibit
hiv
infect
howev
test
bnab
abl
neutral
isol
su
moog
recent
develop
antivir
agent
recogn
two
conserv
epitop
site
gardner
et
al
fusion
recombin
fusion
protein
consist
fc
region
small
sulfopeptid
result
effect
agent
shown
effect
neutral
panel
simian
immunodefici
virus
includ
bnabsresist
viral
isol
gardner
et
al
accordingli
develop
antivir
agent
control
hiv
infect
sever
acut
respiratori
syndrom
coronaviru
ebov
hev
niv
highli
pathogen
broad
rang
host
includ
human
variou
speci
anim
entri
virus
host
cell
depend
cathepsin
l
catl
cellular
lysosom
proteas
requir
process
gsglycoprotein
cleavag
gener
fusion
viral
envelop
cellular
membran
viral
attach
pager
dutch
simmon
et
al
pager
et
al
kaletski
et
al
high
throughput
approach
identifi
molecul
librari
abil
inhibit
catl
block
viral
entri
cell
small
molecul
deriv
shown
effici
inhibit
catlmedi
cleavag
gsglycoprotein
effect
block
sarscov
entri
cell
elshabrawi
et
al
molecul
also
block
entri
ebov
hev
niv
cell
via
inhibit
glycoprotein
cleavag
elshabrawi
et
al
accordingli
identif
small
molecul
inhibit
catl
promis
approach
develop
broadspectrum
antivir
agent
interfer
viruscel
membran
fusion
endocytosi
viral
entri
cell
bind
cellular
receptor
trigger
conform
chang
subunit
fusion
viral
envelop
cellular
membran
wilen
et
al
transmembran
protein
core
consist
three
unit
heptad
repeat
three
unit
unit
surround
unit
antiparallel
manner
form
sixhelix
bundl
structur
conform
chang
sixhelix
bundl
activ
function
mediat
fusion
viral
cellular
membran
togeth
colman
lawrenc
peptid
enfuvirtid
fuzeon
current
clinic
approv
peptid
fusion
inhibitor
bind
interfer
conform
chang
therebi
block
format
activ
sixhelix
bundl
structur
eckert
kim
although
enfuvirtid
effect
control
wildtyp
variant
enfuvirtid
treatment
result
resist
variant
also
resist
revers
transcriptas
inhibitor
zidovudin
proteas
inhibitor
ritonavir
eckert
kim
thu
develop
nextgener
inhibitor
hr
urgent
recent
homolog
human
troponin
type
interact
kinas
like
protein
identifi
screen
dna
librari
human
bone
marrow
cell
yeast
twohybrid
method
share
homolog
enfuvirtid
bind
sixhelix
bundl
inhibit
infect
variou
strain
report
variant
common
motif
wgrlegrrt
exhibit
potent
activ
inhibit
infect
appar
common
motif
use
lead
develop
optim
inhibitor
control
infect
similar
sixhelix
bundl
structur
report
mediat
entri
class
envelop
virus
host
cell
includ
coronaviru
paramyxoviru
liu
et
al
wang
et
al
sixhelix
bundl
structur
appear
optim
target
develop
broadspectrum
antivir
agent
achiev
end
sequenc
paramyxoviru
ndv
coronaviru
ibv
system
analyz
primari
structur
helix
consist
heptad
repeat
contain
seven
commonli
residu
abcdefg
n
replac
nonconserv
site
b
c
f
g
charg
residu
glutam
acid
lysin
follow
screen
reveal
novel
peptid
au
vnkkieeidkkieelnkkleelekkleevnkk
abl
complet
inhibit
singl
doubl
infect
cell
ndv
ibv
vitro
vivo
wang
et
al
furthermor
tag
cholesterol
unit
nterminu
au
result
cau
prolong
halflif
au
vivo
also
increas
potenc
control
viral
infect
exampl
intramuscular
inject
chicken
cau
one
day
prior
viru
inocul
everi
day
three
time
viral
inocul
result
protect
anim
ndv
infect
vivo
studi
demonstr
feasibl
use
antivir
peptid
clinic
applic
control
viral
infect
rna
polymeras
essenti
replic
numer
rna
virus
te
velthui
novel
nucleosid
analog
inhibitor
specif
viral
rna
polymeras
exhibit
broadspectrum
antivir
activ
virus
includ
filovirus
flavivirus
arenavirus
paramyxovirus
coronavirus
bunyavirus
warren
et
al
treatment
complet
protect
golden
hamster
death
caus
infect
yfv
flaviviru
treatment
also
improv
symptom
includ
weight
loss
viremia
also
complet
protect
cynomolgu
macaqu
infect
marburg
viru
hemorrhag
fever
viru
filovirida
famili
even
administ
h
viral
infect
juland
et
al
warren
et
al
similarli
block
replic
variou
virus
paramyxovirus
orthomyxovirus
etc
via
specif
inhibit
viral
rna
polymeras
interestingli
treatment
affect
mrna
synthesi
protein
translat
host
cell
krumm
et
al
abl
specif
target
viral
rna
polymeras
without
caus
side
effect
host
addit
resist
viral
variant
detect
anim
treatment
krumm
et
al
warren
et
al
pyrazin
deriv
favipiravir
target
viral
rnadepend
rna
polymeras
treatment
inhibit
almost
rna
virus
without
affect
dna
rna
synthesi
host
cell
clinic
reportedli
effect
control
ebov
infect
oestereich
et
al
de
clercq
addit
treatment
ifvainfect
cell
result
detect
resist
variant
mendenhal
et
al
accordingli
agent
target
viral
rna
polymeras
optim
candid
broadspectrum
antivir
agent
fulli
develop
control
rna
virus
dihydroorot
dehydrogenas
dhodh
dehydrogen
dihydroorot
orot
acid
key
step
biosynthesi
de
novo
pyrimidin
gener
uracil
essenti
replic
viral
rna
dna
evan
guy
compound
identifi
highthroughput
screen
smallmolecularweight
compound
abl
target
dhodh
interrupt
biosynthesi
pyrimidin
inhibit
replic
virus
includ
neg
strand
rna
virus
ifva
b
posit
strand
rna
virus
hepat
c
viru
hcv
denv
dna
virus
vacv
adenoviru
hoffmann
et
al
compound
treatment
also
caus
damag
viral
genom
rna
reduc
viral
infect
ortizriano
et
al
cotreat
ribavirin
enhanc
therapeut
efficaci
control
lcmv
ortizriano
et
al
ribavirin
broadspectrum
antivir
agent
approv
treatment
rsv
hcv
infect
naik
tyagi
ribavirin
guanosin
analog
use
inhibit
synthesi
viral
rna
parker
ribavirin
also
inhibit
rna
polymeras
hcv
interfer
viral
replic
induc
format
gtp
analog
rtp
caus
translat
error
viral
protein
cannon
et
al
shah
et
al
addit
ribavirin
known
inhibit
replic
rna
dna
virus
via
distinct
mechan
replic
viru
via
distinct
mechan
differ
cell
type
depend
intracellular
ribavirin
metabol
shah
et
al
interestingli
treatment
ribavirin
alon
show
modest
effect
viral
replic
hcvinfect
patient
howev
combin
ifn
dramat
improv
longterm
antivir
respons
patient
dixit
perelson
anoth
dhodh
inhibitor
compound
identifi
silico
fragmentbas
drug
design
fbdd
inhibit
human
murin
dhodh
vitro
dosedepend
manner
konteati
low
microto
nanomolar
level
highli
effect
inhibit
replic
human
murin
cytomegalovirus
hcmv
mcmv
well
marschal
et
al
vivo
studi
show
treatment
mice
mgkgday
day
result
signific
suppress
mcmv
replic
variou
organ
includ
salivari
gland
lung
liver
spleen
marschal
et
al
antimycin
isol
streptomyc
kaviengensi
display
potent
activ
control
equin
enceph
virus
eev
infect
treatment
antimycin
increas
surviv
rate
eevinfect
mice
reduc
viral
replic
raveh
et
al
antimycin
also
abl
control
infect
variou
rna
virus
includ
member
togavirida
flavivirida
bunyavirida
picornavirida
paramyxovirida
famili
raveh
et
al
interestingli
antimycin
inhibit
cellular
mitochondri
electron
transport
chain
de
novo
pyrimidin
synthesi
indic
host
mitochondri
electron
transport
viabl
target
identifi
broadspectrum
antivir
agent
commerci
antiprotozo
agent
nitazoxanid
recent
identifi
firstinclass
broadspectrum
antivir
agent
inhibit
replic
variou
rna
dna
virus
includ
hiv
ifv
denv
hcv
hbv
jev
rossignol
nitazoxanid
shown
mobil
ca
result
chronic
subleth
stress
er
disrupt
viral
protein
glycosyl
traffick
ashiru
et
al
base
phylogenet
analysi
positivesens
rna
virus
picornavirus
calicivirus
coronavirus
recogn
member
picornaviruslik
superclust
virus
possess
proteas
respect
contain
typic
chymotrypsinlik
fold
catalyt
triad
dyad
cy
residu
nucleophil
xia
kang
act
key
enzym
proteolyt
process
viral
polyprotein
viru
replic
wang
liang
target
superclust
member
aldehyd
bisulfit
adduct
share
common
dipeptidyl
residu
identifi
abil
inhibit
enzymat
activ
via
coval
bind
nucleophil
cy
residu
conserv
catalyt
site
kim
et
al
kim
et
al
develop
broadspectrum
antivir
agent
control
viral
infect
picornaviruslik
superclust
member
format
viral
ribonucleoprotein
vrnp
complex
consist
viral
rna
rna
polymeras
nucleoprotein
essenti
process
replic
negativesens
singlestrand
rna
virus
ifva
replic
ifv
genom
rna
nucleu
vrnp
complex
transloc
cytoplasm
assembl
viral
nucleocapsid
seri
nuclear
export
pathway
nuclear
export
receptor
chromosom
region
mainten
mediat
pathway
mao
yang
leptomycin
b
lmb
highli
specif
inhibitor
lmb
treatment
block
export
vrnp
nucleu
cytoplasm
therebi
suppress
assembl
ifvb
particl
dauber
et
al
lmb
also
shown
inhibit
replic
dna
virus
park
et
al
although
lmb
treatment
effect
toxic
detect
anim
perwitasari
et
al
thu
lmb
need
studi
modifi
improv
therapeut
valu
control
viral
infect
human
homolog
exportin
mediat
transport
leucinerich
nuclear
export
signaldepend
cellular
protein
rna
cell
growth
differenti
askjaer
et
al
nuclear
export
vrnp
complex
mediat
interact
viral
nuclear
export
protein
ifva
neumann
et
al
also
verdinexor
small
molecul
antagonist
perwitasari
et
al
vitro
studi
show
abl
select
effect
inhibit
replic
variou
ifv
b
strain
includ
pandem
highli
pathogen
aiv
recent
emerg
vivo
studi
show
prophylact
therapeut
administr
protect
mice
ifv
ifv
treatment
reduc
product
viral
particl
proinflammatori
cytokin
lung
nonsignific
toxic
perwitasari
et
al
thu
appear
promis
broadspectrum
antivir
agent
recent
report
envelop
virus
ebov
util
cellular
endosom
sort
complex
requir
transport
escrt
pathway
releas
progeni
infect
cell
escrt
pathway
also
major
escap
rout
envelop
virus
vottel
schubert
bucci
snyder
et
al
dolnik
et
al
tumor
suscept
gene
product
subunit
escrti
luyet
et
al
phenol
compound
target
inhibit
viral
bud
ebov
treatment
mgkgday
day
protect
mice
ebovcaus
death
treatment
also
interven
hcv
ifva
infect
via
inhibit
kinch
et
al
recent
lu
group
report
serv
target
z
protein
ptapl
domain
junv
caus
argentin
hemorrhag
fever
facilit
viral
bud
lu
et
al
use
structur
interact
site
target
silico
screen
competit
bind
molecul
novel
compound
identifi
abil
block
interact
protein
z
lu
et
al
inhibit
bud
junv
particl
known
ptap
ldomaincontain
protein
gener
requir
separ
rna
viral
particl
host
cell
chen
lamb
studi
show
effect
inhibit
ptapdepend
bud
arenaviru
filoviru
retroviru
lu
et
al
thu
compound
use
lead
compound
develop
broadspectrum
antivir
agent
control
viral
bud
cell
abl
promptli
repair
damag
rang
cell
membran
cytoplasm
endomembran
howev
viral
particl
incap
repair
damag
viral
envelop
mcmahon
gallop
type
ii
photosensit
deriv
aromat
methyl
dien
rhodanin
wolf
et
al
treatment
cell
result
gener
singlet
oxygen
membran
bilay
mediat
lipid
oxid
perman
chang
biophys
properti
viral
envelop
result
interrupt
viruscel
fusion
contrast
treatment
result
perman
damag
cell
membran
due
abil
cell
repair
lipid
biosynthesi
wolf
et
al
thu
treatment
abl
irrevers
damag
viral
envelop
bilay
structur
host
cell
membran
protect
cell
fusion
envelop
virus
includ
bunyavirus
filovirus
poxvirus
arenavirus
paramyxovirus
flavivirus
ifva
vitro
wolf
et
al
use
lead
compound
new
class
membranetarget
photosensit
ie
deriv
develop
improv
solubl
bioavail
vivo
applic
vitro
studi
show
abl
increas
level
cell
vivo
studi
show
treatment
significantli
delay
death
rvfv
bunyavirus
infect
mice
vigant
et
al
recent
mastoparan
natur
host
defens
peptid
nhp
isol
invertebr
wasp
shown
enter
viral
envelop
interact
lipid
compon
albiol
matan
castilla
mastoparanderiv
peptid
abl
alter
structur
viral
envelop
directli
inactiv
infect
envelop
virus
includ
rhabdovirus
flavivirus
herpesvirus
poxvirus
ifva
sampl
et
al
possibl
ifva
envelop
less
organizedord
envelop
virus
vsv
rhabdovirus
contribut
ifv
resist
dom
et
al
mukhopadhyay
et
al
harri
et
al
preexposur
vsv
particl
significantli
reduc
infect
vsv
vivo
sampl
et
al
thu
recogn
lead
compound
develop
broadspectrum
agent
control
viral
infect
target
viral
envelop
indol
deriv
arbidol
shown
block
interact
cell
membran
hcv
glycoprotein
inhibit
viral
entri
fusion
cell
boriskin
et
al
arbidol
also
inhibit
viral
replic
hcv
alter
cytoplasm
protein
essenti
intracellular
traffick
eg
clathrin
coat
compon
element
cytoskeleton
viral
replic
eg
membran
web
hinder
membran
rearrang
involv
viral
bud
arbidol
clinic
shown
inhibit
infect
envelop
virus
ifva
coronaviru
well
nonenvelop
reoviru
thu
arbidol
consid
broadspectrum
antivir
agent
worthi
develop
blais
et
al
arbidol
clinic
use
treat
viral
infect
russia
sinc
howev
approv
use
western
countri
blais
et
al
gener
antivir
agent
cau
target
viral
attach
viruscel
membran
fusionendocytosi
specif
virus
howev
treatment
often
result
drugresist
viral
variant
specif
virus
limit
potenti
develop
broadspectrum
antivir
agent
agent
inhibit
viral
rna
polymeras
noncytotox
abil
block
replic
variou
rna
virus
without
result
drugresist
viral
variant
posit
candidaci
develop
optim
broadspectrum
agent
inhibit
rna
virus
compound
interrupt
biosynthesi
pyrimidin
cell
appear
broadspectrum
antivir
agent
control
rna
dna
virus
treatment
result
drugresist
viral
variant
block
viral
assembl
cytoplasm
appear
anoth
promis
broadspectrum
antivir
agent
control
rna
dna
virus
target
cellular
export
escrt
system
inhibit
viral
bud
without
result
drugresist
viral
variant
although
compound
target
cellular
machineri
abl
act
broadspectrum
antivir
agent
potenti
side
effect
patient
need
address
whether
combin
agent
optim
control
variou
virus
remain
determin
host
cellular
defens
first
hurdl
viral
infect
howev
virus
abl
util
cellular
machineri
viral
replic
grow
knowledg
help
identifi
broadspectrum
antivir
agent
target
cellular
machineri
defens
program
cell
death
metabol
present
follow
subsect
tabl
figur
type
ifn
alpha
beta
interferon
firstlin
cytokin
host
antivir
defens
via
immun
system
rapid
induct
cellular
modul
inhibit
viral
replic
spread
burk
et
al
viral
infect
yield
highli
conserv
pathogenassoci
molecular
pattern
pamp
doublestrand
rna
dsrna
viral
rna
contain
short
hairpin
dsrna
triphosphoryl
end
ppprna
preferenti
activ
host
pattern
recognit
receptor
prr
retino
acid
induc
genei
rigi
relat
receptor
ng
gommerman
ppprnaactiv
rigi
interact
mitochondri
antiviralsign
protein
mav
result
activ
transcript
factor
ifn
regulatori
ikkrel
kinas
induc
ifn
gene
express
schlee
et
al
wilkin
gale
analog
ppprna
deriv
untransl
region
vsv
genom
schlee
et
al
shown
induc
ifn
express
multipl
innat
antivir
respons
includ
control
infect
ifva
denv
vsv
hcv
vacv
goulet
et
al
olagni
et
al
mice
treat
ppprna
fulli
recov
surviv
lethal
infect
ifv
ppprna
treatment
complet
inhibit
viral
replic
lung
goulet
et
al
secret
type
ifn
virusinfect
cell
may
trigger
antivir
activ
infect
cell
also
surround
uninfect
cell
autocrineor
paracrinedepend
manner
ifn
bind
cell
surfac
ifn
receptor
ifnar
activ
janu
kinas
signal
transduc
activ
transcript
jakstat
pathway
lead
upregul
hundr
ifnstimul
gene
isg
product
itit
ifitm
oligoadenyl
synthetas
oa
burk
et
al
gener
isg
shown
exhibit
wide
rang
antivir
abil
includ
abil
degrad
viral
nucleic
acid
inhibit
viral
gene
express
serv
prr
amplifi
ifn
signal
elev
ifn
express
bisbal
et
al
wilkin
gale
may
act
ubiquitin
crossreact
protein
moral
lenschow
abl
inhibit
ubiquitin
gag
protein
interact
gag
import
releas
particl
cell
pincet
lei
may
block
escrt
pathway
see
viral
assembl
bud
disrupt
cell
releas
viral
particl
ebov
aslv
moral
lenschow
also
involv
isgyl
viral
protein
contribut
ifnmedi
inhibit
viru
replic
ifninduc
ubiquitin
ligas
mediat
isgyl
ifva
protein
directli
inhibit
viral
replic
tang
et
al
zhao
et
al
also
abl
help
isg
isgyl
inhibit
ubiquitin
degrad
lu
et
al
stabil
form
complex
creb
bind
protein
cbp
transloc
nucleu
activ
transcript
ifn
isg
gene
prinaraki
et
al
shown
play
critic
role
innat
immun
respons
dna
rna
virus
overexpress
result
increas
antivir
activ
vitro
vivo
knockdown
result
increas
replic
vsv
sev
ndv
cell
shi
et
al
demonstr
antivir
abil
ifit
interferon
induc
protein
tetratricopeptid
repeat
ifitm
ifninduc
transmembran
protein
two
famili
involv
ifn
activ
distinct
genet
function
ifit
ifitm
show
broadspectrum
antivir
activ
interfer
viral
replic
transmiss
virul
diamond
farzan
four
human
famili
member
three
rodent
famili
member
identifi
ifit
inhibit
viral
infect
multipl
mechan
suppress
translat
initi
hui
et
al
bind
uncap
incomplet
cap
viral
rna
pichlmair
et
al
sequest
viral
protein
eg
hpv
rna
cytoplasm
terenzi
et
al
hand
human
ifitm
famili
compos
four
member
murin
ifitm
compos
ifitm
protein
travers
cell
membran
abund
endosom
lysosom
prevent
envelop
virus
cross
endosom
lysosom
membran
penetr
cytoplasm
diamond
farzan
ifitm
member
also
interfer
membran
fusion
endocytosi
viral
particl
effect
inhibit
viral
infect
envelop
virus
ifv
ebov
sarscov
denv
brass
et
al
huang
et
al
shown
abl
limit
ifva
hemagglutinin
attach
phase
viral
replic
contribut
control
ifva
infect
vivo
brass
et
al
feeley
et
al
howev
detail
mechan
ifitm
member
differenti
inhibit
envelop
virus
whether
ifitm
may
interfer
replic
nonenvelop
virus
remain
studi
oasrnas
l
pathway
detect
variou
type
mammalian
cell
bisbal
et
al
upon
activ
viral
dsrna
oa
synthes
oligoadenyl
atp
result
bind
inact
monomer
form
rnase
l
result
dimer
activ
rnase
l
activ
rnase
l
mediat
degrad
viral
rna
contribut
ifn
antivir
activ
chakrabarti
et
al
silverman
weiss
thu
activ
rnase
l
consid
develop
antivir
agent
howev
labil
cytotox
may
optim
antivir
agent
candid
gale
sen
high
throughput
screen
chemic
librari
chembridg
diverset
small
molecul
techniqu
fluoresc
reson
energi
transfer
fret
identifi
seven
compound
effect
activ
rnase
l
micromolar
concentr
thakur
et
al
two
lead
compound
abl
enter
cell
induc
rnase
l
activ
without
show
cytotox
show
broadspectrum
antivir
activ
rna
virus
includ
picornavirus
rhabdovirus
paramyxovirus
retrovirus
thakur
et
al
addit
novel
tetrahydrocarbazol
shown
induc
signific
increas
seven
isg
includ
oasl
trail
treatment
result
growth
inhibit
cell
infect
hpv
adenoviru
ebv
possibl
via
induct
isg
harvey
et
al
howev
exact
mechan
antivir
activ
still
need
clarif
apoptosi
autophagi
two
major
form
program
cell
death
play
essenti
role
homeostasi
also
surviv
multicellular
organ
lockshin
zakeri
klionski
apoptosi
autophagi
distinguish
basi
cell
morpholog
chang
hacker
lockshin
zakeri
apoptosi
character
activ
proteolyt
caspas
format
apoptot
bodi
mediat
degrad
cellular
organel
autophagi
character
format
autophagosom
sequestr
transport
cytoplasm
materi
includ
damag
protein
organel
lysosom
degrad
regard
selfeat
catabol
respons
viral
infect
induct
apoptosi
may
limit
viral
product
spread
adjac
cell
simultan
promot
host
innat
inflammatori
respons
taylor
et
al
upton
chan
howev
virus
ebov
abl
escap
apoptot
control
revers
process
facilit
viral
replic
respect
martin
et
al
fuentesgonzalez
et
al
infect
virus
paramyxovirus
orthomyxovirus
may
result
activ
phosphatidylinositol
akt
pathway
block
apoptosi
benefit
viral
replic
sun
et
al
liu
et
al
diehl
schaal
activ
akt
phosphoryl
downstream
transcript
factor
promot
degrad
suppress
cellular
antivir
respons
see
program
cell
death
lei
et
al
pathway
inhibitor
aktiv
identifi
high
throughput
screen
inhibitor
ramaswami
et
al
sun
et
al
aktiv
shown
inhibit
replic
paramyxovirus
rsv
interestingli
although
pathway
involv
replic
vsv
aktiv
abl
inhibit
vsv
replic
sun
et
al
dunn
et
al
also
shown
inhibitor
effect
inhibit
product
lcmv
junv
viral
particl
without
caus
cell
toxic
urata
et
al
dsrnaactiv
caspas
oligomer
draco
new
antivir
agent
current
preclin
studi
draco
consist
three
compon
dsrna
recognit
domain
deriv
protein
kinas
r
pkr
activ
defens
ifn
pathway
apoptot
proteas
activ
induc
apoptot
caspas
pathway
transduct
peptid
deriv
tat
protein
enter
cell
rider
et
al
thu
draco
approach
induc
ifn
apoptosi
pathway
control
virusinfect
cell
studi
show
draco
abl
induc
death
cell
infect
either
envelop
nonenvelop
virus
undetect
toxic
uninfect
cell
rider
et
al
draco
reportedli
effect
control
infect
variou
virus
includ
orthomyxoviru
flaviviru
picornaviru
arenaviru
bunyaviru
reoviru
adenoviru
rider
et
al
anim
studi
show
administr
draco
day
prior
viral
infect
day
post
viral
infect
significantli
reduc
product
viral
particl
morbid
anim
intranas
infect
ifv
rider
et
al
draco
appear
optim
broadspectrum
antivir
agent
develop
autophagi
basic
cellular
mechan
degrad
unnecessari
dysfunct
cellular
compon
action
lysosom
recycl
cellular
compon
klionski
autophagi
reportedli
involv
prosurviv
prodeath
pathway
depend
individu
cellular
event
nikoletopoul
et
al
autophagi
recogn
play
role
control
intracellular
pathogen
fuel
innat
adapt
immun
respons
viral
infect
liang
et
al
nakashima
et
al
klionski
virus
block
format
autolysosom
target
autophag
protein
inhibit
autophagi
allow
viral
replic
orvedahl
et
al
nonstructur
protein
footandmouth
diseas
viru
fmdv
interact
facilit
viral
replic
gladu
et
al
virus
flavivirus
orthomyxovirus
coronavirus
may
also
util
autophag
machineri
facilit
viral
replic
prentic
et
al
jackson
et
al
zhou
et
al
heaton
randal
dumit
dengjel
thu
whether
autophagi
optim
machineri
target
develop
broadspectrum
antivir
agent
remain
address
treatment
autophagi
inhibitor
baicalin
natur
product
isol
scutellariaradix
result
suppress
express
autophag
complex
autophagosom
marker
cell
zhu
et
al
baicalin
treatment
shown
suppress
viral
replic
flaviviru
denv
vitro
moghaddam
et
al
baicalin
treatment
also
attenu
ifvainduc
autophagi
cell
effect
increas
surviv
rate
mice
infect
ifv
nayak
et
al
zhu
et
al
mammalian
target
rapamycin
mtor
shown
play
role
regul
cell
growth
autophagi
respons
chang
nutrit
suppli
growth
factor
stress
jung
et
al
mtor
serinethreonin
kinas
mediat
signal
block
autophagi
via
phosphoryl
treatment
cell
mtor
inhibitor
rapamycin
lead
dephosphoryl
result
induct
autophagi
jung
et
al
infect
may
result
induct
mtor
protein
synthesi
downregul
autophagi
lymphocyt
dendrit
cell
contribut
blockag
host
immun
respons
zhou
spector
gougeon
piacentini
van
der
vlist
et
al
rehman
et
al
treatment
rapamycin
block
infect
cell
vitro
roy
et
al
oswaldricht
et
al
inhibit
infect
human
leucocyt
scid
mice
nicoletti
et
al
nicoletti
et
al
combin
rapamycin
viral
entri
inhibitor
vicriviroc
synergist
enhanc
suppress
infect
vitro
heredia
et
al
rapamycin
treatment
also
shown
reduc
replic
avian
leukemia
viru
alv
liu
et
al
result
suggest
rapamycin
potenti
candid
antihiv
drug
develop
howev
adequ
use
agent
suppress
activ
autophagi
control
viral
infect
still
need
address
ubiquitin
ubiquitinationlik
modif
eg
sumoyl
wide
involv
stabil
local
recycl
cellular
protein
well
interact
protein
substrat
hershko
hochstrass
ubiquitin
ubiquitinationlik
modif
play
role
regul
cellular
protein
nuclear
transport
proteolysi
translat
autophagi
antivir
respons
ubiquitin
posttransl
modif
via
attach
ubiquitin
ub
substrat
protein
ub
small
regulatori
protein
mw
kda
found
almost
eukaryot
cell
ubiquitin
initi
induc
interact
ubactiv
enzym
activ
ub
follow
interact
ubconjug
enzym
ub
ligas
form
isopeptid
bond
carboxyl
terminu
ub
group
lysin
residu
target
protein
pickart
subsequ
result
ubtag
protein
bind
proteasom
degrad
recycl
accordingli
assembl
ubiquitinationinvolv
compon
proteasom
togeth
construct
ubproteasom
system
up
coux
et
al
ubiquitin
ubiquitinationlik
modif
known
play
import
role
regul
viral
compon
proteasom
degrad
hbv
x
protein
kim
et
al
hcv
core
protein
shirakura
et
al
hav
proteas
schlax
et
al
logic
enhanc
host
cell
defens
abil
via
modul
ubiquitin
system
control
viral
infect
howev
report
virus
abl
util
up
help
viral
replic
isaacson
ploegh
exampl
ifva
b
util
up
modifi
viral
protein
hivgag
respect
facilit
viral
replic
ubiquitin
hivgag
major
structur
protein
enhanc
bind
subunit
escrti
see
viral
assembl
bud
assembl
viral
particl
complet
viral
bud
releas
pornillo
et
al
klinger
schubert
sumoyl
play
import
role
modul
assembl
viral
particl
pal
et
al
rossman
lamb
wu
et
al
virus
also
abl
util
up
subvert
interfer
host
innat
defens
system
nfkb
protein
vif
nef
vpu
vpr
essenti
viral
replic
import
evad
host
immun
system
strebel
exampl
uniqu
zincfing
motif
vif
recruit
ubiquitin
ligas
form
complex
ubiquitin
human
antivir
protein
degrad
huthoff
tower
guo
et
al
nfkb
sequest
ikb
cytoplasm
viral
infect
ebv
may
result
activ
nfkb
upsdepend
degrad
ikb
lead
upregul
varieti
antivir
gene
magnani
et
al
mingyan
et
al
sun
cesarman
howev
ifva
abl
util
nfkbdepend
signal
pathway
via
degrad
ikb
activ
nfkb
viral
replic
ludwig
planz
report
proteasom
inhibitor
carbobenzoxylleucyllleucyllleucin
peptid
aldehyd
lactacystin
bortezomib
abl
block
nfkb
activ
via
inhibit
ikb
degrad
omura
et
al
palombella
et
al
hideshima
et
al
treatment
inhibit
ifva
replic
widjaja
et
al
treatment
cell
bortezomib
noncytotox
level
significantli
reduc
ifva
vsv
replic
dudek
et
al
proteasom
inhibitor
abl
reduc
viral
replic
three
ifv
strain
includ
apuerto
treatment
ifvinfect
mice
result
reduc
viral
replic
lung
increas
mice
surviv
without
side
effect
haasbach
et
al
paramyxovirus
sev
rsv
may
induc
ubiquitin
stat
evad
host
ifn
respons
see
interferon
ifn
sev
c
protein
rsv
ns
protein
abl
induc
ubiquitin
respect
degrad
garcin
et
al
elliott
et
al
treatment
sevor
rsvinfect
cell
reduc
viral
replic
dosedepend
manner
watanab
et
al
lupfer
pastey
ten
famili
virus
util
up
complet
replic
success
infect
calistri
et
al
treatment
lactacystin
effect
block
matur
bud
infect
particl
schubert
et
al
klinger
schubert
vottel
schubert
proteasom
inhibitor
also
shown
interfer
replic
herpesvirus
delboy
et
al
coronavirus
yu
lai
rotavirus
et
al
thu
promis
develop
optim
broadspectrum
noncytotox
antivir
agent
inhibit
up
mucu
play
import
role
protect
epitheli
cell
invad
pathogen
respiratori
gastrointestin
urogenit
visual
auditori
system
anim
thornton
sheehan
martinez
et
al
mucin
major
compon
mucu
famili
high
molecular
weight
glycoprotein
hundr
kda
produc
epitheli
tissu
vertebr
invertebr
mucin
abl
form
gellik
barrier
protect
cell
viral
attach
lieleg
et
al
porcin
mucin
isol
gastric
mucou
epithelium
shown
form
shield
trap
viral
particl
hpv
ifv
ifva
size
nm
respect
buck
et
al
well
hiv
nm
hsv
nm
lai
et
al
lieleg
et
al
porcin
gastric
mucin
may
use
antivir
agent
futur
biomed
applic
cellular
function
protein
directli
indirectli
involv
replic
brass
et
al
dziuba
et
al
understand
role
cellular
protein
associ
pathway
viral
replic
help
design
new
strategi
develop
broadspectrum
antivir
agent
inhibitor
aktiv
mtor
inhibitor
rapamycin
proteasom
inhibitor
eventu
agent
specif
interven
replic
target
virus
howev
challeng
drug
toxic
host
gener
resist
viral
progeni
remain
address
current
develop
broadspectrum
antivir
agent
target
viral
infect
modul
host
defens
system
substanti
advanc
field
virolog
pharmaceut
significantli
contribut
health
care
human
anim
howev
concern
viral
resist
associ
agent
target
viral
compon
nonspecif
side
effect
associ
agent
target
cellular
machineri
accordingli
reduc
viral
resist
increas
drug
specif
current
challeng
address
whether
combin
use
agent
target
viral
compon
cellular
machineri
may
improv
antivir
efficaci
reduc
viral
resist
minim
toxic
control
viral
infect
epidem
viral
diseas
need
clarifi
